173 related articles for article (PubMed ID: 27079440)
1. Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.
Sanches Jde S; de Aguiar RB; Parise CB; Suzuki JM; Chammas R; de Moraes JZ
Cancer Sci; 2016 Apr; 107(4):551-5. PubMed ID: 27079440
[TBL] [Abstract][Full Text] [Related]
2. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
[TBL] [Abstract][Full Text] [Related]
4. Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.
Alishekevitz D; Bril R; Loven D; Miller V; Voloshin T; Gingis-Velistki S; Fremder E; Scherer SJ; Shaked Y
Mol Cancer Ther; 2014 Jan; 13(1):202-13. PubMed ID: 24150126
[TBL] [Abstract][Full Text] [Related]
5. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
7. Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response.
Silva TA; Aguiar RB; Mori M; Machado GE; Hamaguchi B; Machado MFM; Moraes JZ
Gene Ther; 2023 Aug; 30(7-8):598-602. PubMed ID: 36482074
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.
Xu A; Zhang L; Chen Y; Lin Z; Li R
Cancer Immunol Immunother; 2017 Feb; 66(2):181-192. PubMed ID: 27872951
[TBL] [Abstract][Full Text] [Related]
10. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
Kong DH; Kim MR; Jang JH; Na HJ; Lee S
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Yang H; Jager MJ; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
[TBL] [Abstract][Full Text] [Related]
12. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
13. Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies.
Li W; Ran Y; Li M; Zhang K; Qin X; Xue X; Zhang C; Hao Q; Zhang W; Zhang Y
BMC Biotechnol; 2013 Sep; 13():77. PubMed ID: 24073737
[TBL] [Abstract][Full Text] [Related]
14. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
15. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of radiation response with bevacizumab.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
J Exp Clin Cancer Res; 2012 Apr; 31(1):37. PubMed ID: 22538017
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
18. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
Finn RS; Bentley G; Britten CD; Amado R; Busuttil RW
Liver Int; 2009 Feb; 29(2):284-90. PubMed ID: 18482274
[TBL] [Abstract][Full Text] [Related]
19. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
20. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.
Reiners KS; Gossmann A; von Strandmann EP; Böll B; Engert A; Borchmann P
J Immunother; 2009 Jun; 32(5):508-12. PubMed ID: 19609243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
